GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » YoY EBITDA Growth

Novelion Therapeutics (STU:QLTA) YoY EBITDA Growth : 30.54% (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Novelion Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2019 was 30.54%.

Novelion Therapeutics's EBITDA per Share for the three months ended in Mar. 2019 was €-0.45.

Novelion Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Novelion Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics YoY EBITDA Growth Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.77 7.79 -28.78 9.54 61.60

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.29 -170.16 90.99 212.65 30.54

Novelion Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Novelion Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2018 is calculated as:

YoY EBITDA Growth (A: Dec. 2018 )
=(EBITDA per Share (A: Dec. 2018 )-EBITDA per Share (A: Dec. 2017 ))/ | EBITDA per Share (A: Dec. 2017 ) |
=(-1.001--2.607)/ | -2.607 |
=61.60 %

Novelion Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2019 is calculated as:

YoY EBITDA Growth (Q: Mar. 2019 )
=(EBITDA per Share (Q: Mar. 2019 )-EBITDA per Share (Q: Mar. 2018 )) / | EBITDA per Share (Q: Mar. 2018 )) |
=(-0.448--0.645)/ | -0.645 |
=30.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » YoY EBITDA Growth
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.